ArticleAsian Pacific journal of cancer prevention : APJCP2025
Decreased Expression Levels Of PIWIL2, PIWIL3 and PIWIL4 Are Associated with Poor Prognosis and Worse Survival in Bladder Cancer Patients.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PIWIL4: from biological characteristics to disease pathogenesis and clinical applications.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer (BC) remains one of the most prevalent and recurrent malignancies worldwide. Identification of early biomarkers and prognostic indicators is vital for improving diagnostic accuracy and therapeutic outcomes. PIWI-interacting RNA pathway proteins (PIWILs), known regulators of gene silencing and genome stability, have emerged as potential biomarkers in various cancers. This study evaluates the expression patterns of PIWIL1-4 in BC patients and investigates their prognostic value.
methodsTumor and adjacent tissues were collected from 220 BC patients, along with urine samples from both patients and 70 healthy controls. Total RNA was extracted, followed by cDNA synthesis and real-time PCR for PIWIL1-4. Protein expression of PIWIL2 was evaluated by immunohistochemistry. Clinical data, including staging and histopathological features, were analyzed. In silico analysis (cBioPortal, miRNet) was performed to assess PIWIL gene variants and miRNA associations. Receiver operating characteristic (ROC) curves, logistic regression, and survival analysis were conducted for diagnostic and prognostic assessments.
resultsExpression of all four PIWILs was significantly downregulated in both tissue and urine samples of BC patients compared to controls (p < 0.001). ROC analysis showed high sensitivity and specificity for PIWILs in distinguishing BC from controls (AUC ≥ 0.927). Logistic regression confirmed their diagnostic and prognostic relevance (p < 0.001). PIWIL2, PIWIL3, and PIWIL4 were significantly associated with tumor recurrence (p ≤ 0.01), while all four PIWILs correlated with patient survival. Immunohistochemical analysis of PIWIL2 supported its expression relevance. In silico findings revealed a 7% structural variant frequency for PIWIL2 and functional associations with tumor suppressor miRNAs.
conclusionPIWIL1-4, particularly PIWIL2, are significantly downregulated in BC and hold promise as non-invasive diagnostic and prognostic biomarkers. Their expression correlates with recurrence and survival, suggesting clinical utility for improving bladder cancer management. Further studies are recommended to validate these findings in larger cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.